Abstract: Spark plug has center electrode having leg portion extending in an axis direction, brim portion located at rear end side with respect to the leg portion and protruding outwards in a radial direction with respect to the leg portion and connecting portion connecting the leg portion and the brim portion; insulator having penetration hole and supporting the center electrode; and seal member filling the penetration hole and fixing the brim portion and the insulator. The center electrode satisfies “(D1-D2)/D1?0.06”, where a maximum value of a radius of the brim portion is D1, and a minimum value of the radius of the brim portion is D2, also satisfies “L2/L1?0.30”, where a size of the center electrode along the axis direction is L1, and a size along the axis direction from boundary between the connecting portion and the leg portion to a center of gravity of the center electrode is L2.

Abstract: Spark plug has center electrode having leg portion extending in an axis direction, brim portion located at rear end side with respect to the leg portion and protruding outwards in a radial direction with respect to the leg portion and connecting portion connecting the leg portion and the brim portion; insulator having penetration hole and supporting the center electrode; and seal member filling the penetration hole and fixing the brim portion and the insulator. The center electrode satisfies “(D1-D2)/D1 ? 0.06”, where a maximum value of a radius of the brim portion is D1, and a minimum value of the radius of the brim portion is D2, also satisfies “L2/L1 ? 0.30”, where a size of the center electrode along the axis direction is L1, and a size along the axis direction from boundary between the connecting portion and the leg portion to a center of gravity of the center electrode is L2.

Abstract: The method for diagnosing cerebrospinal fluid hypovolemia includes injecting saline into a subdural space of a subject in a decubitus position, raising an upper body of the subject, and then determining whether the subject has headache or not, or headache of the subject is relieved or not.

Abstract: The method for diagnosing cerebrospinal fluid hypovolemia includes injecting saline into a subdural space of a subject in a decubitus position, raising an upper body of the subject, and then determining whether the subject has headache or not, or headache of the subject is relieved or not.

Abstract: The objective of the present invention to provide a method for accurately and safely specifying a leakage part of cerebrospinal fluid in a cerebrospinal fluid hypovolemia patient, and a method for effectively treating cerebrospinal fluid hypovolemia with utilizing the specifying method. The method for specifying a leakage part of cerebrospinal fluid in a cerebrospinal fluid hypovolemia patient according to the present invention is characterized in comprising the steps of injecting saline into a bone-marrow space of a spine of the cerebrospinal fluid hypovolemia patient, and detecting the cerebrospinal fluid or the injected saline leaked from a dura mater of the spine to specify the leakage part of the cerebrospinal fluid.

Abstract: The objective of the present invention to provide a method for accurately and safely specifying a leakage part of cerebrospinal fluid in a cerebrospinal fluid hypovolemia patient, and a method for effectively treating cerebrospinal fluid hypovolemia with utilizing the specifying method. The method for specifying a leakage part of cerebrospinal fluid in a cerebrospinal fluid hypovolemia patient according to the present invention is characterized in comprising the steps of injecting saline into a bone-marrow space of a spine of the cerebrospinal fluid hypovolemia patient, and detecting the cerebrospinal fluid or the injected saline leaked from a dura mater of the spine to specify the leakage part of the cerebrospinal fluid.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.

Abstract: The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.

Abstract: An information processing apparatus displays contents data including first and second image data when viewing an object from a first direction and a second direction. The information processing apparatus includes an apparatus main body, a multi-view display device including at least first to second display units provided individually at a first face and a second face of the apparatus main body, and a control unit for displaying the first to second image data on the first to second display units.

Abstract: Pyrimidine-5-carboxamide derivatives represented by a general formula (I) or salts thereof [wherein each symbol has the following meaning; X: O, S, NR1, CO, NR1CO, CONR1, C═N—OR1 or a bond, Y: a lower alkylene group which may be substituted by OR1 or —NHR1, or a bond, Z: O, NR2 or a bond, A: H, or a lower alkyl which may have a substituent, a —CO-lower alkyl which may have a substituent, an aryl which may have a substituent, a heteroaryl which may have a substituent, a cycloalkyl which may have a substituent or a nitrogen-containing saturated heterocyclic group which may have a substituent, B: an aryl which may have a substituent or a heteroaryl group which may have a substituent, R1, R2: H, a lower alkyl or a —CO-lower alkyl group].